These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32029404)

  • 1. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG).
    Aparicio T; Canouï-Poitrine F; Caillet P; François E; Cudennec T; Carola E; Albrand G; Bouvier AM; Petri C; Couturier B; Phelip JM; Bengrine-Lefevre L; Paillaud E
    Dig Liver Dis; 2020 May; 52(5):493-505. PubMed ID: 32029404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
    Phelip JM; Tougeron D; Léonard D; Benhaim L; Desolneux G; Dupré A; Michel P; Penna C; Tournigand C; Louvet C; Christou N; Chevallier P; Dohan A; Rousseaux B; Bouché O
    Dig Liver Dis; 2019 Oct; 51(10):1357-1363. PubMed ID: 31320305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
    Gouverneur A; Rouyer M; Grelaud A; Robinson P; Colombani F; Terrebonne E; Smith D; Fourrier-Réglat A; Noize P
    Fundam Clin Pharmacol; 2017 Feb; 31(1):104-109. PubMed ID: 27600062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer.
    Weinberg BA; Marshall JL; Hartley M; Salem ME
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):116-28. PubMed ID: 27057810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.
    Aranda E; Aparicio J; Alonso V; Garcia-Albeniz X; Garcia-Alfonso P; Salazar R; Valladares M; Vera R; Vieitez JM; Garcia-Carbonero R
    Clin Transl Oncol; 2015 Dec; 17(12):972-81. PubMed ID: 26669312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
    Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
    Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF).
    Greillier L; Gauvrit M; Paillaud E; Girard N; Montégut C; Boulahssass R; Wislez M; Pamoukdjian F; Corre R; Cabart M; Caillet P; Belaroussi Y; Frasca M; Noize P; Wang P; Mebarki S; Mathoulin-Pelissier S; Couderc AL
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
    BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapies.
    Vogel A; Hofheinz RD; Kubicka S; Arnold D
    Cancer Treat Rev; 2017 Sep; 59():54-60. PubMed ID: 28738235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.
    Ciliberto D; Staropoli N; Caglioti F; Chiellino S; Ierardi A; Ingargiola R; Botta C; Arbitrio M; Correale P; Tassone P; Tagliaferri P
    Crit Rev Oncol Hematol; 2018 May; 125():69-77. PubMed ID: 29650279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
    Maillet M; Dréanic J; Dhooge M; Mir O; Brezault C; Goldwasser F; Chaussade S; Coriat R
    Anticancer Drugs; 2014 Nov; 25(10):1215-9. PubMed ID: 24858536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
    Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
    Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice.
    Bekaii-Saab T; Kim R; Kim TW; O'Connor JM; Strickler JH; Malka D; Sartore-Bianchi A; Bi F; Yamaguchi K; Yoshino T; Prager GW
    Clin Colorectal Cancer; 2019 Mar; 18(1):e117-e129. PubMed ID: 30598357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
    Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
    Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design.
    André T; Saunders M; Kanehisa A; Gandossi E; Fougeray R; Amellal NC; Falcone A
    Future Oncol; 2020 Feb; 16(4):21-29. PubMed ID: 31914811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales.
    Bullement A; Underhill S; Fougeray R; Hatswell AJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):e143-e151. PubMed ID: 29110922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer.
    Martinez-Perez J; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Opin Drug Saf; 2018 Jun; 17(6):643-650. PubMed ID: 29745737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current status of palliative care for patients with unresectable metastatic colorectal cancer in China: a questionnaire-based survey].
    Wang F; Chen DL; Wang ZX; He Y; Li J; Zhang SZ; Chen G; Xu JM; Yuan XL; Zhang YQ; Xu RH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul; 27(7):718-725. PubMed ID: 39004987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.